Bessemer Group Inc. cut its stake in Amgen Inc. (NASDAQ:AMGN) by 11.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 60,809 shares of the medical research company’s stock after selling 7,651 shares during the quarter. Bessemer Group Inc.’s holdings in Amgen were worth $10,475,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Bank of New York Mellon Corp raised its stake in shares of Amgen by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock worth $1,403,676,000 after buying an additional 195,200 shares during the period. Schwab Charles Investment Management Inc. raised its stake in shares of Amgen by 1.6% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 2,894,780 shares of the medical research company’s stock worth $474,947,000 after buying an additional 45,403 shares during the period. UBS Asset Management Americas Inc. raised its stake in shares of Amgen by 3.1% during the 1st quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock worth $446,250,000 after buying an additional 81,362 shares during the period. Swiss National Bank raised its stake in shares of Amgen by 26.5% during the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after buying an additional 551,600 shares during the period. Finally, Ameriprise Financial Inc. raised its stake in shares of Amgen by 0.7% during the 1st quarter. Ameriprise Financial Inc. now owns 1,479,687 shares of the medical research company’s stock worth $242,555,000 after buying an additional 10,109 shares during the period. 78.10% of the stock is owned by institutional investors.

Amgen Inc. (NASDAQ AMGN) opened at 185.82 on Monday. The company has a 50-day moving average price of $181.33 and a 200 day moving average price of $170.23. The firm has a market capitalization of $135.59 billion, a P/E ratio of 16.93 and a beta of 1.36. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $191.10.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. Amgen’s revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.84 earnings per share. Analysts expect that Amgen Inc. will post $12.58 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/10/09/bessemer-group-inc-has-10-48-million-holdings-in-amgen-inc-amgn.html.

AMGN has been the subject of several research analyst reports. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $203.00 target price (up from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. BidaskClub raised Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. ValuEngine raised Amgen from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. BMO Capital Markets downgraded Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 26th. Finally, Mizuho reaffirmed a “buy” rating and set a $198.00 target price (up from $183.00) on shares of Amgen in a research note on Thursday, September 28th. Ten research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $189.99.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.